论文部分内容阅读
目的探讨肝癌衍生生长因子(HDGF)在Ⅰ期非小细胞肺癌(NSCLC)中的表达及其临床意义,以及可能的作用机制。方法应用免疫组化SP法检测118例Ⅰ期NSCLC和30例正常肺组织中HDGF的表达,同时检测VEGF的表达以及Ki-67抗原标记率。结果HDGF在肺癌组织中表达普遍上调,正常肺组织HDGF评分为52.23±10.35,肺癌组织评分为156.73±70.95,差异有统计学意义(P<0.01);HDGF表达与病理类型显著相关,腺癌的HDGF评分明显高于鳞癌,差异有统计学意义(P=0.001),而与其他临床病理因素均无明显相关性。肺癌组织中HDGF评分随着VEGF表达强度的增强而升高,VEGF低表达组的HDGF评分为142.81±59.84,高表达组为171.77±81.07,差异有统计学意义(P=0.028);肺癌组织中Ki-67抗原标记率随着HDGF表达的增加而升高,HDGF低表达组的Ki-67抗原标记率为17.80%±5.63%,HDGF高表达组的Ki-67抗原标记率为30.49%±7.88%,差异有统计学意义(P=0.001)。单因素生存分析表明,HDGF高表达组的5年生存率(40.0%)较低表达组(77.5%)明显降低,差异有统计学意义(P=0.008)。多因素生存分析结果表明,HDGF为Ⅰ期NSCLC的独立预后指标(RR=1.011,P=0.002)。结论HDGF在Ⅰ期NSCLC中的表达普遍上调,可以作为Ⅰ期NSCLC的独立预后指标。HDGF可能通过促进细胞增殖和新生血管生成在Ⅰ期NSCLC的发生发展中起到重要的作用。
Objective To investigate the expression and clinical significance of hepatocellular carcinoma-derived growth factor (HDGF) in stage Ⅰ non-small cell lung cancer (NSCLC) and its possible mechanism. Methods The expression of HDGF in 118 cases of stage Ⅰ NSCLC and 30 cases of normal lung tissue was detected by immunohistochemical SP method. The expression of VEGF and the labeling rate of Ki-67 antigen were also detected. Results The expression of HDGF in lung cancer was generally up-regulated. The HDGF score in normal lung tissue was 52.23 ± 10.35 and the lung cancer tissue score was 156.73 ± 70.95, the difference was statistically significant (P <0.01). HDGF expression was significantly correlated with pathological type, HDGF score was significantly higher than squamous cell carcinoma, the difference was statistically significant (P = 0.001), and no significant correlation with other clinicopathological factors. The HDGF score of lung cancer increased with the increase of VEGF expression. The HDGF score of low VEGF expression group was 142.81 ± 59.84, while the high expression group was 171.77 ± 81.07, the difference was statistically significant (P = 0.028) Ki-67 antigen labeling rate increased with the increase of HDGF expression, HDGF low expression group Ki-67 antigen labeling rate was 17.80% ± 5.63%, HDGF high expression group Ki-67 antigen labeling rate was 30.49% ± 7.88 %, The difference was statistically significant (P = 0.001). Univariate survival analysis showed that the 5-year survival rate (40.0%) in HDGF-overexpressing group was significantly lower than that in the low expression group (77.5%), the difference was statistically significant (P = 0.008). Multivariate survival analysis showed that HDGF was an independent prognostic indicator of stage I NSCLC (RR = 1.011, P = 0.002). Conclusion The expression of HDGF in stage Ⅰ NSCLC is generally up-regulated and can be used as an independent prognostic indicator for stage Ⅰ NSCLC. HDGF may play an important role in the occurrence and development of stage I NSCLC by promoting cell proliferation and neovascularization.